amgen weight loss news

Amgen Stock Dives

Amgen Drug Delivers More Weight Loss Than Competitors

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

MarketWatch on MSN · 11h

Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms

Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year,

Barron's on MSN · 1d

Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know.

Amgen stock was dropping sharply Tuesday after releasing what looked like positive data from a Phase 2 study for its experimental monthly weight-loss shot MariTide.Overweight or obese patients on MariTide lost 20% of their body weight on average,

Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

22h

What's Next for Amgen Obesity Drug After Investors Disappointed by Results

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Amgen price target lowered to $330 from $360 at RBC Capital

RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results